Bayer Aktiengesellschaft (LON:0P6S)
London
· Delayed Price · Currency is GBP · Price in EUR 26.40
+0.86 (3.37%)
At close: Jul 1, 2025
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Crop Science | 22.26B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Crop Science Growth | -3.92% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Pharmaceuticals | 18.13B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Pharmaceuticals Growth | 1.60% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Consumer Health | 5.87B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Consumer Health Growth | 0.87% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Enabling Functions and Consolidation | 19.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Enabling Functions and Consolidation Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
All Other Segment | 327.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
All Other Segment Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBITDA by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Crop Science Adjusted EBITDA | 4.33B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Crop Science Adjusted EBITDA Growth | -12.71% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Pharmaceuticals Adjusted EBITDA | 4.72B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Pharmaceuticals Adjusted EBITDA Growth | -7.71% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Consumer Health Adjusted EBITDA | 1.37B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Consumer Health Adjusted EBITDA Growth | 1.03% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Enabling Functions and Consolidation Adjusted EBITDA | -352.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Enabling Functions and Consolidation Adjusted EBITDA Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
All Other Segment Adjusted EBITDA | 62.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
All Other Segment Adjusted EBITDA Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Europe/Middle East/Africa | 13.98B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Europe/Middle East/Africa Growth | -0.32% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
North America | 16.48B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
North America Growth | 2.68% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Asia/Pacific | 8.07B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Asia/Pacific Growth | 1.65% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Latin America | 8.08B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Latin America Growth | -10.76% |
Log In |
Log In |
Log In |
Log In | Upgrade
|